Skip to main content
HCPCS J7526 · Level II · Part B drug

J7526: mycophenolate mofetil (Cellcept IV), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J7526

Billing unit
5 MG
Inj mycophenola mofetil 5 mg
ASP payment limit
$0.20
October 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J7526 is the Level II code for Injection, mycophenolate mofetil, 5 mg, billed per 5 MG. The Medicare Part B ASP payment limit for October 2026 is $0.20 per billing unit. Under OPPS it carries status indicator N. J7526 is billed in units of 5 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. Other HCPCS codes whose descriptor names mycophenolate mofetil: J7524 (oral route); J7529 (oral route; suspension); J7530 (Myhibbin from Azurity Pharmaceuticals, Inc.; oral route; suspension). The ASP crosswalk maps 6 NDCs to it, sold as Cellcept IV, Mycophenolate Mofetil IV by Genentech, Inc., Endo USA, Inc., Mylan Institutional LLC. No current Billing and Coding Article lists J7526, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J7526 at $0.20 per 5 MG for October 2026, derived from manufacturer average sales price plus 6%. Beneficiary coinsurance is 20%.

ASP payment limits for J7526
QuarterPayment limitPerCoinsurance
October 2026$0.205 MG20%
July 2026n/a5 MG—
CMS note: Added October 2026

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 6 NDCs from 5 labelers to J7526. Report the NDC in the claim's drug segment and bill the number of J7526 units that equals the quantity administered divided by 5 MG; the last column gives units per full package.

NDCs that crosswalk to J7526
NDCDrug nameLabelerPackage sizeBilling units / package
00004-0298-09Cellcept IVGenentech, Inc.1 × 4400
42023-0172-04Mycophenolate Mofetil IVEndo USA, Inc.1 × 4400
67457-0386-81Mycophenolate Mofetil IVMylan Institutional LLC1 × 4400
71288-0803-21Mycophenolate Mofetil IVMeitheal Pharmaceuticals Inc.1 × 4400
71288-0803-92Mycophenolate Mofetil IVMeitheal Pharmaceuticals Inc.1 × 4400
72485-0415-04Mycophenolate Mofetil IVArmas Pharmaceuticals Inc.1 × 4400

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for J7526 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for J7526 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J7526 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J7526 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J7526 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J7526 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J7526 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Common denials for J7526 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J7526

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J7526

What does HCPCS code J7526 describe?

J7526 is defined by CMS as "Injection, mycophenolate mofetil, 5 mg". Each billing unit represents 5 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J7526 a CPT code?

No. J7526 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as mycophenolate mofetil (Cellcept IV); CPT codes are five-character codes maintained by the AMA. On a Part B claim J7526 reports the drug itself in 5 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J7526 in October 2026?

The ASP-based payment limit is $0.20 per 5 MG, with 20% beneficiary coinsurance. Commercial payers use their own fee schedules.

Which NDCs map to J7526?

The October 2026 ASP crosswalk lists 6 NDCs from 5 labelers: Cellcept IV (Genentech, Inc.); Mycophenolate Mofetil IV (Endo USA, Inc.); Mycophenolate Mofetil IV (Mylan Institutional LLC); Mycophenolate Mofetil IV (Meitheal Pharmaceuticals Inc.). For example NDC 00004-0298-09 (package size 1) equals 400 billing units of J7526.

Does J7526 have NCCI bundling edits?

No active practitioner PTP pairs list J7526 as a column-1 or column-2 code in the v323r0 release.

J7526 vs J7524: what is the difference?

Both are HCPCS Level II codes whose descriptor names mycophenolate mofetil. What sets J7524 apart: oral route. J7526 is billed per 5 mg, limit $0.20; J7524 is billed per 5 mg, limit $0.002. Report the code whose descriptor matches the product and setting in the record.

J7526 vs J7529: what is the difference?

Both are HCPCS Level II codes whose descriptor names mycophenolate mofetil. What sets J7529 apart: oral route; suspension. J7526 is billed per 5 mg, limit $0.20; J7529 is billed per 5 mg, limit $0.034. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.